Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

Oncology Practice Insider

ASCO’s Oncology Practice Insider provides the latest news, information, and educational tools to assist with the successful management of oncology practice and the delivery of high quality patient care. OPI offers updates on ASCO programs, services, and cancer-related health policy, Medicare news, and billing and coding best practices. To sign up for the biweekly Oncology Practice Insider newsletter, please complete this form.

Date
CMS recently added a third low-volume threshold criterion for determining Merit-based Incentive Payment System (MIPS) eligibility for 2019. Clinicians and groups are excluded from MIPS if they:
Your eligibility status may have changed for the Merit-based Incentive Payment System (MIPS). Be sure to check the Quality Payment Program Participation Status Tool to view your final 2019 eligibility status. Your initial eligibility status was based on review of Medicare Part B claims and Provider Enrollment, Chain and Ownership System (PECOS) data from October 1, 2017, to September 30, 2018.
Registration is now open for the third annual Expanded Access Summit, which will take place January 27–29, 2020, at the National Press Club in Washington, D.C.
ASCO recently submitted comments to the Centers for Medicare & Medicaid Services’ (CMS) Request for Information on its conceptualized Oncology Care First payment model and recommended that the agency also adopt the society’s updated Patient-Centered Oncology Payment (PCOP) model in order to improve care delivery and lowers costs. “Through the framework laid out in the PCOP model, we believe CMS can achieve its goal of a truly multi-payer model that improves care delivery and reduces costs,” said ASCO President Howard A. "Skip" Burris, III, MD, FACP, FASCO.
In the latest ASCO in Action Podcast, ASCO CEO, Dr. Clifford A. Hudis, discusses the updates that will affect oncologists in the 2020 Medicare Physician Fee Schedule final rule, which outlines changes to Part B reimbursement policies and the Quality Payment Program.   ASCO’s goal will always be “to ensure that oncologists can provide the right treatment, at the right time,” says Dr. Hudis, “and we aim to help CMS implement policies that advance that goal.”  
The Centers for Medicare and Medicaid Services (CMS) recently posted a new webpage for the Victimized Provider Program (VPP) to assist Medicare providers that have had their identities stolen and used to bill Medicare for services, diagnostic tests, or medical equipment that was never provided or not medically necessary. When a fraudster inappropriately bills Medicare and receives payment using a provider’s stolen identity, the legitimate physician or provider may be held liable for any overpayments.
“I still find such power in helping someone see light in a very dark time.” In new social video, Dr. Dizon shares why he lives to conquer cancer In a new I Live to Conquer Cancer™ video, Don S. Dizon, MD, FACP, FASCO, an oncologist at the Lifespan Cancer Institute at the Rhode Island Hospital, shares his passion and commitment in caring for people with cancer. 
On December 3, 2019, the Food and Drug Administration approved atezolizumab (TECENTRIQ®, Genentech Inc.) in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. Read more.